A growing population doesn't guarantee a successful launch. Neither does a clinically supported product or a shortage of a specialty. Leadership needs to know who needs the offering, who will refer or buy, how payment works, and whether the organization is ready to deliver, before the launch budget becomes a commitment.
Tell us the market you're weighing and where you are in the decision. We'll get back to you.
We've got your note and will get back to you shortly. If it's urgent, email info@arccentrx.com.
Start with population trends, demand, competition, and available capacity. Then make the review specific to what's entering the market.
Competitor enrollment, market share, provider relationships, and network coverage.
Patient needs, specialty availability, referral patterns, and payer participation.
Who makes the clinical decision, who approves the purchase, and which channels customers use.
Public sources are a starting point. CMS publishes Medicare Advantage enrollment, service area, and penetration data, and HRSA's Area Health Resources Files cover workforce, facilities, population, and utilization. Combine them with local knowledge and appropriately obtained claims data, and read that data carefully: low utilization may reflect limited access, an underserved population, or incomplete data. It doesn't automatically mean demand is absent.
Local referral partners know things a market report can't show: where patients wait, which services are hard to access, and what makes them comfortable referring someone. Start those conversations early.
Discussions, roundtables, professional outreach, and the right press activity build awareness before the doors open. The point is to learn whether the offering fits, and to build relationships the organization can support.
A launch team should be able to say what the organization does, whom it serves, and why someone should choose it.
Which patients are appropriate, how to refer, what access looks like, and what happens after the referral.
The product's role, the evidence behind it, the purchasing process, and the support available after adoption.
Traction takes more than outreach volume. People need to understand the offering and trust the team to deliver it.
A facility launch, a health plan expansion, and a device launch each have different requirements. These are the questions leadership should be able to answer.
Are the required permits, inspections, licenses, and insurance in place?
Are the necessary people committed and available for the launch?
Are the applicable facility and provider requirements complete?
Is the intended payment or purchasing route established?
Can the team receive, schedule, serve, and follow up with patients or customers?
Do referral partners or buyers understand how to engage?
What happens if a provider withdraws or an approval is delayed?
A published launch date shouldn't hide a readiness gap. Leadership needs to know which conditions must be met before opening, and who owns each one.
How the offering reaches its customer is one of the most consequential market entry decisions. A direct channel can look like more margin and more control, but that preference has to be tested against how customers evaluate, purchase, and adopt the product.
FDA notes that device market authorization and payer coverage are separate decisions, and providers and payers make their own calls about whether to use, recommend, cover, or pay for a device. That distinction belongs in the commercial plan early. You can challenge an established buying model, but first understand it, and have evidence for why customers will adopt the alternative.
First-year revenue matters, but leadership also needs indicators that show whether the launch is gaining ground, in order.
Who has heard about the offering?
Who is responding and asking for more information?
Which referral partners, providers, or buyers are actively involved?
Are those relationships producing patients, purchases, or enrollment?
Is the organization serving those people well?
Is the resulting activity moving toward the financial plan?
For care delivery, clinical outcomes and patient experience belong alongside volume and revenue. A referral relationship is hard to sustain if the people sent to you don't receive dependable care. When results fall short, leadership should know whether the gap is awareness, conversion, delivery capacity, or the economics of the offering.
A medical device company entering the U.S. had clinical support for its product but needed a commercial route that matched its readiness and the way customers bought. It had resisted distribution in favor of a direct approach, and was weighing a pharmaceutical and reimbursement direction before the documentation was ready.
We challenged the resistance to distribution, secured the company's largest distribution relationship, and supported the rollout. The company signed an approximately $30 million distribution agreement, and was sold 26 months after our engagement began. The agreement and the sale are separate outcomes; the lesson is how rethinking the channel created a viable path into the market.
Leadership should be able to explain the demand, the customer, the route to purchase or referral, what delivery requires, and the measures that will show whether the plan is working. Stay open to what the assessment reveals. The right strategy may need a different channel, offering, partner, or timeline than the one first envisioned.
ArcCentrx helps healthcare leaders assess markets, develop commercial and referral strategies, and align the people, processes, and partnerships a launch needs.